Spectinomycin: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 10: | Line 10: | ||
==US Brand Names== | ==US Brand Names== | ||
TROBICIN<sup>®</sup> | TROBICIN<sup>®</sup> (''DISCONTINUED'') | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
'''[[Spectinomycin description|Description]]''' | ''' [[Spectinomycin description|Description]]''' | ||
'''| [[Spectinomycin clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Spectinomycin clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Spectinomycin microbiology|Microbiology]]''' | '''| [[Spectinomycin microbiology|Microbiology]]''' | ||
Latest revision as of 02:48, 4 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Spectinomycin is an aminocyclitol antibiotic produced by the bacterium Streptomyces spectabilis.
Category
Aminocyclitol
US Brand Names
TROBICIN® (DISCONTINUED)
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied
Mechanisms of Action
It binds to the 30S ribosomal subunit in invading bacteria and interrupts protein synthesis.